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Summary Lymphoproliferative syndrome with well differentiated lymphocytes and moderate lymphocytosis
in the peripheral blood includes a heterogenous group of disorders, that present often difficulties in
classification. We have studied the lymphocyte markers (ER, EMR, slg and T3, T4, T8 antigens) in 36 cases
who had lymphocytic infiltration in the bone marrow and peripheral lymphocyte counts < 15 x 1091-1. Four
cases (11.1%) had the characteristics of T8 lymphocytosis and 31 had a B cell monoclonal proliferation in the
peripheral blood. Of these, four were slg-, EMR+, 19 were slg+, EMR+ and 8 were sIg+, EMR-. Most
patients (17/32) had the clinical picture of stage 0 and I B-CLL. Six cases presented as pure splenomegalic
form of CLL, three had the features of immunocytic lymphoma and five had the features of lymphocytic
lymphoma. It is concluded that the majority of lymphoproliferative disorders presenting with moderate
lymphocytosis represent early forms of B-CLL. Occasionally cases of lymphocytic or immunocytic lymphoma
may present problems of differential diagnosis since there may be a dissociation of phenotypic characteristics
of lymphocytes between tissues and peripheral blood.
Until recently the clinical diagnosis of chronic
lymphocytic leukaemia (CLL) was based on Rai's
staging system (Rai et al., 1975) which accepted as
minimum necessary criteria a sustained increase of
peripheral blood small lymphocytes above
15 x 109 1-1 and a lymphocytic infiltration of the
bone marrow with more than 30% small mature
lymphocytes. However during the last decade the
phenotypic analysis of lymphocyte membrane
surface markers has been introduced for the classi-
fication of lymphoproliferative disorders. The
demonstration of a clonal expansion of B or T
lymphocytes may be taken as an indication of a
neoplastic process even in cases with low lympho-
cytosis in the peripheral blood and may contribute
greatly to the correct diagnosis of cases which
otherwise present difficulties in classification.
The typical phenotypic pattern for B-CLL which
represents 95% of all cases of CLL is characterised
by weak expression of surface immunoglobulin (slg)
which is monoclonal with respect to light chain and
strong expression of the receptor for mouse rosette
formation (Galton & MacLennan, 1982). However
cases of lymphocytic lymphoma and some cases of
follicular lymphoma with bone marrow involvement
may show the same phenotype although the clinical
presentation may vary.
In this work we have studied the peripheral
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blood lymphocyte surface markers in cases of
lymphoproliferative syndrome who had bone
marrow infiltration with small mature lymphocytes
and blood lymphocyte count lower than
15 x 10 1-1 and correlated the finding to clinical
aspects of the disease.
Materials and methods
Patients
Thirty six consecutive untreated patients who
presented with lymphocytosis (< 15 x lO9 1 1
lymphocytes) and bone marrow lymphocytic
infiltration >25% were included in this study. In a
few cases, the lymphocytic infiltration could not be
shown in the bone marrow smear but the bone
marrow biopsy showed a nodular pattern of the
lymphocytic infiltrate. The patients, 28 males and 8
females, had a median age of 68 years (48-85
years). All patients had a complete haematological
investigation which included bone marrow and
lymph node biopsies if lymphadenopathy was
present. Staging of the disease was performed
according to Rai et al. (1975).
Methods
Peripheral blood lymphocytes were isolated from
fresh heparinised blood after gradient centrifugation
in a sodium-metrizoat-ficoll solution (Lymphoprep,
Nyegaard, Oslo, Norway). The washed mono-
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nuclear cells were analysed for surface markers as
follows:
B cells were identified by surface immunoglobulin
staining using direct immunofluorescence after
incubation with FITC-conjugated goat anti-human
IgG F(ab')2 and goat antihuman K or A F(ab')2 light
chains (Kallestad, Chaska, MN).
Erythrocyte mouse rosette formation (EMR) was
studied after incubation of the mononuclear cells
with freshly prepared untreated mouse erythrocytes
(Catovsky et al., 1976). Normal control values were
7.4+5.8% of mononuclear cells.
T cells (ER) were estimated after rosetting with 2-
aminoethyl isothiouronium bromide (AET) treated
sheep red blood cells (Kaplan & Clark, 1974).
T lymphocyte subpopulations were determined in
the separated mononuclear cells using indirect
immunofluorescence after incubation with mono-
clonal mouse antibodies (Reinherz & Schlossman,
1980) of the OKT series OKT3, OKT4, OKT8
(Ortho, Raritan, New Jersey) and further staining
with FITC-conjugated goat antimouse IgG (Meloy
Lab., Springfield).
Serum immunoglobulin levels were determined by
radial immunodiffusion with commercial immuno-
diffusion plates (Meloy Lab., Springfield).
Results
The lymphocyte count in the peripheral blood of
the patients ranged from 2.6 x 109P1 to
14.2x 1091-1 (mean 8.15x 1091-1) and the
percentage of lymphocytes from 50% to 95%
(mean 70%).
The analysis of the B and T cell markers revealed
that of the 36 patients 31 had B-cell and four had a
T-cell monoclonal proliferation in the peripheral
blood.
B-cell lymphoproliferative syndrome
According to clinical histological and laboratory
findings cases with B-cell lymphoproliferative
syndrome could be classified as follows. Twelve had
stage 0 B-CLL, 5 had stage I and one stage II B-
CLL and 6 had probably a pure splenomegalic
form (PSF) of B-CLL without any lymph node
involvement (Tables I to III).
The mean lymphocyte count and the mean
percentage of EMR and ER did not differ in these
three groups (Table IV). Of the 12 stage 0 patients
3 had undetectable slg and 5 very weak expression
of slg. Two had low values of EMR formation (4%
and 9%) and 2 had borderline values (21% and
24% respectively). The monoclonal sIg was of the K
(kappa) type in all cases. Of the 5 patients with
stage I CLL one had undetectable slg and 4 type K
slg. The percentage of EMR formation was
increased in all but one who had a borderline value
(24%).
Of the 6 patients with the splenomegalic form of
CLL 5 had a type K and one a type A (lambda) sIg.
The percentage of EMR formation was increased in
4 but in 2 that had a strong expression of slg it was
low (4% and 8% respectively). One of these cases
had 25% prolymphocytes in the peripheral blood.
In 8 patients on clinical and histological grounds
the diagnosis of non Hodgkin's lymphoma (NHL)
was made. Three had in the lymph nodes the
picture of immunocytic lymphoma (IcL) with
lymphoplasmacytoid cells but in two of them the
phenotype of the peripheral blood lymphocytes was
that of B-CLL with increased percentage of EMR.
The other 5 had the histological picture of lympho-
cytic lymphoma (LcL). One of these patients had
no detectable monoclonal B cell poulations in the
peripheral blood. Four out of the 5 patients had a
normal percentage of EMR (Table III).
The geometric mean values of serum immuno-
globulin concentration in the different groups
studied is shown in Table IV and the individual
values in Figure 1.
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Figure 1 Values of serum immunoglobulins in B-cell
lymphoproliferative syndrome. 0: stage 0 B-CLL; 0:
stage I B-CLL; A: Pure splenomegalic form of B-
CLL; *: NHL. Hatched areas: normal mean values
+s.d.
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Table I B-Cell lymphoproliferative syndrome (B-CLL stage 0). Clinical data and surface marker
analysis.
Percent of total lymphocytes
No. BM Ly count Predominant
cases Sex Age Ly% LN SP x 1091 1 sIg light chain EMR ER T4 T8
1 M 71 60 - 12.5 UD UD 76 7 0 2
2 F 55 65 - 10.5 UD UD 32 62 32 28
3 M 55 60 - - 14.2 UD UD 85 14 9 4
4 M 50 NP - - 8.4 34(w) 24(K) 62 50 15 11
5 M 70 50 - 6.8 70(w) 80(K) 9 28 6 3
6 M 68 70 -- 7.1 53(w) 48(K) 48 48 21 7
7 M 52 40 - - 8.4 45(w) 20(K) 30 22 6 5
8 M 48 50 - - 7.2 56 23(K) 45 26 20 18
9 F 60 NP - - 13.6 7 24 60 24 16
10 M 68 60 - 8.8 16 11(K) 21 58 40 11
11 F 77 35 - 9.7 59 52(K) 56 22 18 3
12 M 85 25 12.5 57(str) 63(K) 6 36
UD: undetectable; NP: nodular pattern in the bone marrow biopsy; (w): weak staining; (str): strong
staining.
Table II B-Cell lymphoproliferative syndrome (B-CLL stage I-II)
Percent total lymphocytes
Case BM Ly count Predominant
no. Sex Age Ly% LN SP x 109 sIg light chain EMR ER T4 T8
13 M 51 NP + - 7.6 UD UD 51 36 22 9
14 M 58 40 + - 7.5 63(w) 20(A) 63 25 25 20
15 M 80 60 + - 7.6 57 28(K) 35 36 NS NS
16 F 77 50 + - 8.8 35 ND 50 45 ND ND
17 M 48 25 + - 8.3 43 38(K) 24 30 25 11
18 M 55 40 + + 7.0 54 34(K) 48 38 25 23
UD: undetectable; NP: nodular pattern; ND: not done; NS: non specific staining.
Table III B-Cell lymphoproliferative syndrome (pure splenomegalic form of B-CLL and non Hodgkin's
lymphoma)
Percent of total lymphocytes
Case BM Ly count Predominant
no. Sex Age Ly% LN SP Diagnosis x 109 sIg light chain EMR ER T4 T8
19 M 70 50 - + PSF 13.6 70 20(K) 28 66 49 17
20 F 70 40 - + PSF 2.7 61 57(K) 54 45 14 26
21 M 77 90 - + PSF 3.8 46 33(K) 51 36 9 5
22 M 78 40 - + PSF 6.1 45 38(K) 44 29 7 6
23 M 70 50 - + PSF 11.5 78(str) 78(K) 4 32 NS NS
24 M 71 60 - + PSF 11.5 90(str) 85(K) 8 15 6 8
25 F 62 80 + + IcL 7.8 66 1(2) 68 29 13 5
26 M 68 50 + + IcL 3.9 52 50(2) 1 48 32 28
27 M 70 60 + - IcL 7.0 34 55(K) 55 45 32 18
28 F 6 65 + + LcL 5.1 8 7 68 26 18
29 M 48 NP + - LcL 2.6 53 47(K) 4 45 14 12
30 F 72 90 + + LcL 9.9 45(w) 45(2) 26 20 22 20
31 M 70 30 - + LcLa 9.3 47 42(K) 1 15 8 15
32 M 59 80 + - LcL 4.7 63 58(K) 3 NS NS NS
str: strong staining.
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Table IV B-Cell lymphoproliferative syndrome. Mean values of immunological parameters.
Serum Igs (g1-1)
No. Ly count EMR ER
cases x 1091-1 sIg % % IgG IgA IgM
B-CLL (stage 0) 12 9.97 3 UD 41.2 36.2 10.1 1.8 0.81
+2.64 9 type K +25.3 +19.1 (8.5-12.0) (1.2-2.6) (0.56-1.2)
B-CLL (stage I-II) 6 7.80 1 UD 44.6 35.0 8.0 1.7 0.76
+0.64 5 type K + 15.2 +6.9 (6.6-9.7) (8.-3.3) (0.47-1.22)
B-CLL (PSF) 6 8.20 5 type K 31.5 37.2 11.4 1.7 1.1
+4.58 1 type A +21.7 +19.2 (7.7-16.9) (9.3-3.2) (0.7-1.96)
B-Cell NHL 8 6.28 1 UD 20.6 38.6 11.6 2.3 1.00
+2.62 4 type K +26.7 +18.4 (6.95-19.5) (1.2-4.2) (0.47-2.14)
3 type A
Controls 24 2.28 7.4 81.9 12.1 1.8 1.00
+0.20 +5.8 +7.3 (9.5-15.4) (1.2-2.9) (0.67-1.00)
UD: undetectable.
Table V T-cell lymphoproliferative syndrome
Percent Igs (gi 1)
Diagnosis BM Lymph. count
Case Age/sex (stage) L LN SP x 109J1- sIg ER T3 T4 T8 G A M
33 60/M T-CLL(0) 25% - - 6.8 6 90 76 8 75 16.2 1.05 1.05
34 70/M T-CLL(0) 40% - 3.4 6 89 90 18 63 20.0 4.3 1.50
35 66/M T-CLL(IIS) 20% - + 9.4 1 23 97 6 93 16.5 3.9 1.40 3 63 95 3 94
36 70/M T-CLL(IIS) 25% - spl/my 7.4 12 50 90 7 90 12.0 2.2 2.00
LN: lymph node; SP: spleen.
The mean IgG concentration was lower than
normal for the groups of B-CLL stage 0 and stages
I and II, and the difference was statistically
significant. However 10 of 17 patients had values
within the normal range. In the splenomegalic form
of B-CLL and the cases with NHL the
concentration of IgG was not different from that of
the controls. The mean concentration of IgA and
IgM was within normal limits in all these patients.
T-cell lymphoproliferative syndrome
Four patients had increased T-cells which reacted in
a high percentage with OKT8 monoclonal antibody
(Table V). None of these patients had lymph node
enlargement but two had splenomegaly. Case 4 had
undergone splenectomy for haemolytic anaemia
when tested. The bone marrow was infiltrated with
relatively small numbers of lymphocytes in all these
cases. The level of serum immunoglobulins was
moderately affected in these patients.
Discussion
The study of cell surface markers in lympho-
proliferative disorders with low absolute lympho-
cytosis is interesting for two main reasons: (a) It
may be helpful for the diagnosis, classification and
staging of early forms of CLL. (b) It may
contribute to the differential diagnosis of two
closely related lymphoproliferative diseases which
differ only in the major involvement of the blood -
CLL and lymphocytic lymphoma.
Initially, according to the Rai staging system,
patients with persistent lymphocytosis below
15 x 1091-1 who had bone marrow infiltration
<30% were excluded from the definition of CLL
because many of these patients had lymph node
enlargement and were classified as having lympho-
cytic lymphoma. Rai and his colleagues now accept
a lymphocytic count of 5 x1091 -1 as the lower
limit for the diagnosis of CLL (Galton, 1981).LYMPHOCYTE MARKERS AND LYMPHOPROLIFERATIVE DISORDERS 655
The results of this study showed that the surface
marker analysis of peripheral blood mononuclear
cells confirmed the presence of a monoclonal
expansion of B cells in 31 of the 36 cases with
lymphoproliferative syndrome and moderate
lymphocytosis. Of these 12 had the clinical features
of stage 0 CLL, according to Rai's criteria, 5 had a
stage I disease and one was classified as stage II.
These patients had a monotypic slg and/or
increased numbers of EMR forming cells in the
peripheral blood. Only two had normal percentages
of EMR forming cells whereas in 3 the percentage
of EMR was marginally elevated ranging between
21% and 24%. In one case the diagnosis of B-CLL
was based on the finding of a small increase (24%)
of EMR forming cells.
Gupta et al. (1976b) in their study report in
healthy adult blood donors a mean percentage of
7.4+3.5 for spontaneous rosette formation with
mouse erythrocytes. In another study of 240 CLL
cases Cherchi & Catovsky (1980) report that 4
patients (1.6%) had <30% EMR. In our study the
number of EMR forming cells in healthy control
subjects ranged from 2% to 16%. On the basis of
these studies it may be suggested that in early forms
of B-CLL marginal increases of EMR forming cells
between 20-25% may indicate the presence of a
neoplastic lymphocyte population.
Among the cases with normal or strong
expression of slg 6 patients had splenomegaly
without lymph node enlargement and two of these
patients were negative for EMR but only one had
the clinical features of prolymphocytic leukaemia,
although he was atypical in having low lymphocyte
count. The other patients, in addition to increased
numbers of B cells, had increased percentage of
EMR (28-54%). These findings indicate that the
majority of cases defined on clinical evidence as
PSF of B-CLL (Galton & MacLennan, 1982) have
the classical phenotype of B-CLL.
A slightly increased percentage of EMR has been
found only in one of the 5 cases diagnosed as
having lymphocytic lymphoma. Increased EMR
formation has only rarely been associated with
immunocytic lymphoma and non Hodgkin's
lymphoma (Gupta et al., 1976a; Stein & Toskdorf,
1979).
However it is interesting that two of the three
cases with the histological picture of immunocytic
lymphoma in the lymph nodes had increased
numbers of EMR in the peripheral blood. This
observation confirms the reported findings that in
CLL cells of the malignant clone may be arrested
at different maturation stages having different
homing properties (Cherchi & Catovsky, 1980;
R6bert et al., 1983).
Gordon et al. (1983) investigated neoplastic
populations from cases of B-CLL and found a
variety of patterns of maturation stages ranging
from 'pre-B' to 'secretory-B' forms. Classification
of the cases into 'true' B-CLL and immunocytoma
revealed no strict association of the histopathologic
entities with any particular phenotypic group, since
the presence of lymphoplasmacytoid and/or plasma
cell features in the lymph nodes or bone marrow of
the patients did not necessarily relate to the
predominant phenotype of the leukaemic cells in
the circulation. These observations and our own
findings indicate that only the long follow up of the
patients with moderate lymphocytosis may
demonstrate whether this group of B-lympho-
proliferative disorders will be heterogenous in their
evolution towards CLL of advanced stages,
lymphocytic lymphoma or immunocytoma. It is
interesting that in these cases of B-lympho-
proliferative syndrome with lymphocyte counts
< 15 x 109 1-1 the levels of serum immunoglobulins
and especially those of IgA and IgM are much less
affected than in cases with high lymphocytosis
(Galton & MacLennan, 1982; Economidou et al.,
1984).
Among the 36 patients that were investigated, 4
(11.1%) had the features of T8 lymphocytosis
(Brisbane et al., 1983). Since this disorder usually
presents with low leucocyte counts or neutropenia it
was to be expected that it would be found more
frequently than anticipated among our cases which
were selected on the basis of low lymphocyte counts
(<15x 1091-1).
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